Maraviroc intensification of stable antiviral therapy in HIV-1-infected patients with poor immune restoration: MARIMUNO-ANRS 145 study

Journal of Acquired Immune Deficiency Syndromes

Volumn 61, Issue 5, 2012, Pages 557-564

  Cuzin, Lise ^a   Trabelsi, Selma ^b   Delobel, Pierre ^a,c   Barbuat, Claudine ^d   Reynes, Jacques ^e   Allavena, Clotilde ^f   Peytavin, Gilles ^g   Ghosn, Jade ^h   Lascoux Combe, Caroline ⁱ   Psomas, Christina ^j   Corbeau, Pierre ^j,k   Flandre, Philippe ^b  

^a TOULOUSE UNIVERSITY HOSPITAL   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c Institut de la Santé et de la Recherche Médicale   (France)

^d DEPARTMENT OF NEUROLOGY   (France)

^e MONTPELLIER UNIVERSITY HOSPITAL   (France)

^f NANTES UNIVERSITY HOSPITAL   (France)

^g ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^h BICÊTRE HOSPITAL   (France)

ⁱ SAINT LOUIS HOSPITAL   (France)

^j Nimes University Hospital   (France)

^k INSTITUTE OF HUMAN GENETICS   (France)

more..

Author keywords

CD4 cells count; Drug drug interactions; Maraviroc; Treatment intensification

Indexed keywords

CD4 ANTIGEN; MARAVIROC; RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CYCLOHEXANE DERIVATIVE; TRIAZOLE DERIVATIVE;

ADULT; ANTIVIRAL THERAPY; CD4 LYMPHOCYTE COUNT; CONFERENCE PAPER; DRUG BLOOD LEVEL; DRUG DOSE INTENSIFICATION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE STATUS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; PLASMA PROTEIN BINDING; POOR IMMUNE RESTORATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCREENING TEST; VIRAL TROPISM; VIRUS REPLICATION; AGED; ARTICLE; CD4 CD8 RATIO; CLINICAL TRIAL; DRUG INTERACTION; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; VIRUS LOAD;

AGED; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; CD4-CD8 RATIO; CYCLOHEXANES; DRUG INTERACTIONS; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TRIAZOLES; VIRAL LOAD;

EID: 84873163446     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e318273015f     Document Type: Conference Paper

References (43)

1. Kaufmann GR, Furrer H, Ledergerber B., et al Characteristics, determinants, and clinical relevance of CD4 T cell recovery to, 500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy. Clin Infect Dis. 2005;41:361-372.
2. Lewden C, Chene G, Morlat P., et al HIV-infected adults with a CD4 cell count greater than 500 cells/mm3 on long-term combination antiretrovi-ral therapy reach same mortality rates as the general population. J Acquir Immune Defic Syndr. 2007;46:72-77.
3. Kaplan RC, Kingsley LA, Gange S.J., et al Low CD4+ T-cell count as a major atherosclerosis risk factor in HIV-infected women and men. AIDS. 2008;22:1615-1624.
4. Kesselring A, Gras L, Smit C., et al Immunodeficiency as a risk factor for non-AIDS-defining malignancies in HIV-1-infected patients receiving combination antiretroviral therapy. Clin Infect Dis. 2011;52:1458-1465.
5. Mocroft A, Reiss P, Gasiorowski J., et al Serious fatal and nonfatal non-AIDS-defining illnesses in Europe. J Acquir Immune Defic Syndr. 2010; 55:262-270.
6. Zoufaly A, An der Heiden M, Kollan C, et al. Clinical outcome of HIV-infected patients with discordant virological and immunological response to antiretroviral therapy. J Infect Dis. 2010;203:364-371.
7. Corbeau P, Reynes J. Immune reconstitution under antiretroviral therapy: the new challenge in HIV-1 infection. Blood. 2011;117:5582-5590.
8. Gazzola L, Tincati C, Bellistri G.M., et al The absence of CD4+ T cell count recovery despite receipt of virologically suppressive highly active antiretroviral therapy: clinical risk, immunological gaps, and therapeutic options. Clin Infect Dis. 2009;48:328-337.
9. Abrams D, Levy Y, Losso M.H., et al Interleukin-2 therapy in patients with HIV infection. N Engl J Med. 2009;361:1548-1559.
10. Dinoso JB, Kim SY, Wiegand A.M., et al Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretro-viral therapy. Proc Natl Acad Sci U S A. 2009;106:9403-9408.
11. Schulze zur Wiesch J, van Lunzen J. Hide and seek. Can we eradicate HIV by treatment intensification? J Infect Dis. 2011;203:894-897.
12. Stepanyuk O, Chiang TS, Dever L.L., et al Impact of adding maraviroc to antiretroviral regimens in patients with full viral suppression but impaired CD4 recovery. AIDS. 2009;23:1911-1913.
13. Klein RS. A moving target: the multiple roles of CCR5 in infectious diseases. J Infect Dis. 2008;197:183-186.
14. Fatkenheuer G, Hoffmann C, Slim J., et al Short-term administration of the CCR5 antagonist vicriviroc to patients with HIV and HCV coinfection is safe and tolerable. J Acquir Immune Defic Syndr. 2010;53:78-85.
15. Hardy WD, Gulick RM, Mayer H, et al Two-year safety and virologic efficacy of maraviroc in treatment-experienced patients with CCR5-Tropic HIV-1 infection: 96-week combined analysis of MOTIVATE 1 and 2. J Acquir Immune Defic Syndr. 2010;55:558-564.
16. Sierra-Madero J., Di Perri G, Wood R, et al Efficacy and safety of maraviroc versus efavirenz, both with zidovudine/lamivudine: 96-week results from the MERIT study. HIV Clin Trials. 2010;11:125-132.
17. Saag M, Goodrich J, Fatkenheuer G., et al A double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1. J Infect Dis. 2009;199:1638-1647.
18. Wilkin TJ, Ribaudo HR, Tenorio A.R., et al The relationship of CCR5 antagonists to CD4+ T-cell gain: a meta-regression of recent clinical trials in treatment-experienced HIV-infected patients. HIV Clin Trials. 2010;11:351-358.
19. Pichenot M, Deuffic-Burban S, Cuzin L., et al Efficacy of new antire-troviral drugs in treatment-experienced HIV-infected patients: a meta-analysis of randomized controlled trials. HIV Med. 2012;13:148-155.
20. Corbeau P, Reynes J. CCR5 antagonism in HIV infection: ways, effects, and side effects. AIDS. 2009;23:1931-1943.
21. Guadalupe M, Sankaran S, George M.D., et al Viral suppression and immune restoration in the gastrointestinal mucosa of human immunodeficiency virus type 1-infected patients initiating therapy during primary or chronic infection. J Virol. 2006;80:8236-8247.
22. Else LJ, Taylor S, Back D.J., et al Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the male and female genital tract. Antivir Ther. 2011;16:1149-1167.
23. Else LJ, Taylor S, Back D.J., et al Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the fetal compartment (placenta and amniotic fluid). Antivir Ther. 2011;16:1139-1147.
24. Melica G, Canestri A, Peytavin G., et al Maraviroc-containing regimen suppresses HIV replication in the cerebrospinal fluid of patients with neurological symptoms. AIDS. 2010;24:2130-2133.
25. Raymond S, Delobel P, Mavigner M., et al Development and performance of a new recombinant virus phenotypic entry assay to determine HIV-1 coreceptor usage. J Clin Virol. 2010;47:126-130.
26. EMEA. Product information. Available at: http://www.ema.europa.eu/ema/ index.jsp?curl=pages/medicines/human/medicines/000811/hu-man-med-000689. jsp&jsenabled=true. Accessed January 16, 2012.
27. Jung BH, Rezk NL, Bridges A.S., et al Simultaneous determination of 17 antiretroviral drugs in human plasma for quantitative analysis with liquid chromatography-tandem mass spectrometry. Biomed Chromatogr. 2007; 21:1095-1104.
28. Mc Fadyen L., Jacqmin P, Wade J., et al Maraviroc (MVC) exposure-efficacy relationship in treatment-experienced HIV-1-infected patients. 11th European AIDS Conference/EACS, Madrid, Spain; 2007.
29. ANRS. ANRS scale to grade the severity of adverse events in adults. Available at: http://www.anrs.fr/content/download/2242/12805/file/ANRS-GradeEI- V1-En-2008.pdf. Accessed January 16, 2012.
30. Mavigner M, Delobel P, Cazabat M., et al HIV-1 residual viremia correlates with persistent T-cell activation in poor immunological responders to combination antiretroviral therapy. PLoS One. 2009;4:e7658.
31. Wilkin TJ, Lalama CM, McKinnon J, et al A pilot trial of adding maraviroc to suppressive antiretroviral therapy for suboptimal CD4+ T-cell recovery despite sustained virologic suppression: ACTG A5256. J Infect Dis. 2012;206:534-542.
32. Gandhi RT, Zheng L, Bosch R.J., et al The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial. PLoS Med. 2010;7. pii: e1000321.
33. McMahon D, Jones J, Wiegand A., et al Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy. Clin Infect Dis. 2010;50:912-919.
34. Garrett NJ, Apea V, Nori A., et al Comparison of the rate and size of HIV-1 viral load blips with Roche COBAS TaqMan HIV-1 versions 1.0 and 2.0 and implications for patient management. J Clin Virol. 2012;53:354-355.
35. Okoli C, Siccardi M, Thomas-William S, et al Once daily maraviroc 300 mg or 150 mg in combination with ritonavir-boosted darunavir 800/100 mg. J Antimicrob Chemother. 2012;67:671-674.
36. Rosario MC, Jacqmin P, Dorr P., et al Population pharmacokinetic/ pharmacodynamic analysis of CCR5 receptor occupancy by maraviroc in healthy subjects and HIV-positive patients. Br J Clin Pharmacol. 2008;65(suppl 1):86-94.
37. Arberas Equiluz H., Crespo Guardo A, Maleno M, et al Analysis of in vitro effects of the CCR5 inhibitor maraviroc on human T lymphocytes functionality. 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Rome, Italy; 2011.
38. Rossi R, Lichtner M, De Rosa A, et al In vitro effect of anti-human immunodeficiency virus CCR5 antagonist maraviroc on chemotactic activity of monocytes, macrophages and dendritic cells. Clin Exp Immunol. 2011;166:184-190.
39. Cossarini F, Galli A, Bigoloni A., et al Increased levels of CD4+ T cells expressing CCR5 during effective treatment with MRC. 18th Conference on Retroviruses and Opportunistic Infections, Boston, MA; 2011.
40. Seclen E, Rallon N, Benito J., et al CD4 gains following maraviroc intensification in HIV-infected patients occur in the absence of any impact on IL-7 plasma levels and soluble markers of immune activation or apoptosis. 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Rome, Italy; 2011.
41. Gutiérrez C., Diaz L, Vallejo A., et al Intensification of antiretroviral therapy with a CCR5 antagonist in patients with chronic HIV-1 infection: effect on T cells latently infected. PLoS One. 2011;6:e27864.
42. Hunt P, Shulman N, Hayes T., et al Immunomodulatory Effects of MVC Intensification in HIV-infected Individuals with Incomplete CD4+ T Cell Recovery during Suppressive ART. 18th Conference on Retroviruses and Opportunistic Infections, Boston, MA; 2011.
43. Gonzalez E, Kulkarni H, Bolivar H., et al The influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility. Science. 2005;307:1434-1440.